Article:Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. (5429510)
This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q33677011. Its title is Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. and the publication date was 2017-05-12. The initial author is Songkiat Chantarogh.
Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.
Title: BMC Nephrology
Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review
- Songkiat Chantarogh
- Soamarat Vilaiyuk
- Thipwimol Tim-Aroon
- Suchin Worawichawong
Publication date (epub): 5/2017
Publication date (pmc-release): 5/2017
Publication date (collection): /2017
Juvenile idiopathic arthritis (JIA) is a common rheumatic disease in children and adolescents. Although JIA may cause secondary amyloidosis, this is a rare complication in patients with JIA and other rheumatic diseases. Many previous studies have revealed that common heterozygous or homozygous mutations in the MEFV gene are associated with systemic-onset JIA (SJIA).
We herein report a case involving a 19-year-old female patient with difficult-to-control SJIA. She developed progressive proteinuria without clinical signs or symptoms of edema. Renal amyloidosis was diagnosed by renal pathologic examination, which demonstrated deposition of eosinophilic amorphous material in the interlobular arteries, arterioles, and interstitium. Electron microscopy showed fibrillary material deposits with a diameter of 8 to 10 nm. A heterozygous E148Q mutation in the MEFV gene was identified. Conventional disease-modifying anti-rheumatic drugs and etanercept had been used to treat the SJIA, but the disease could not be controlled. Therefore, we decided to start tocilizumab to control the disease activity. However, the patient was unable to receive a standard dose of tocilizumab in the early period of treatment because of socioeconomic limitations. Her disease course was still active, and proteinuria was found. Therefore, tocilizumab was increased to a dose of 8 mg/kg every 2 weeks (standard dose of SJIA), and the patient exhibited a clinical response within 3 months.
Refractory SJIA associated with renal amyloidosis is an uncommon cause of proteinuria in adolescents. Tocilizumab may be a beneficial treatment for renal amyloidosis in patients with SJIA.
Amyloidosis is a group of systemic or localized diseases characterized by extracellular deposition of amyloid fibrils in multiple organs [, ]. Organ involvement depends on the subtype of amyloidosis. Secondary or reactive amyloidosis can develop in patients with chronic inflammatory diseases and affects multiple organs such as the kidneys, liver, heart, gastrointestinal system, and autonomic nervous system . The amyloidogenic precursor protein in secondary amyloidosis is mainly synthesized by the hepatic system in a chronic inflammatory state. Accumulation of amyloid fibrils leads to progressive dysfunction of affected organs . Juvenile idiopathic arthritis (JIA) is a common rheumatic disease in children and may cause secondary amyloidosis [, ]. However, amyloidosis is still a rare complication in patients with JIA and other rheumatic diseases [, ]. Many previous studies have revealed that common heterozygous or homozygous mutations in the MEFV gene are associated with systemic-onset JIA (SJIA) [–]. We herein report a case involving an adolescent female patient who was diagnosed with SJIA and developed progressive proteinuria. She was found to carry a heterozygous E148Q mutation in the MEFV gene. Renal pathological examination confirmed the diagnosis of amyloidosis. This case will help general practitioners and pediatricians to recognize the etiology of proteinuria in adolescents with JIA.
Clinical history and investigation results
A 19-year-old female Thai patient had been diagnosed with SJIA 10 years previously and had been developing progressive proteinuria for 1 year. Her initial manifestations of SJIA were quotidian fever, polyarthritis, and pericardial effusion. Although she received pulse methylprednisolone, high-dose prednisolone, and multiple disease-modifying anti-rheumatic drugs from her previous hospital (including methotrexate, sulfasalazine, and cyclosporine A), her disease activity remained mostly active. At the age of 13 years, she was referred to Ramathibodi Hospital for proper management by a pediatric rheumatologist. Her blood samples were negative for antinuclear antibody, anti-double-stranded DNA, and HLA-B27 with normal levels of C3 (1550 μg/mL; reference range, 900–1800 μg/mL) and C4 (551 μg/mL; reference range, 100–600 μg/mL). No underlying disease was found in her family members. During the first year of follow-up at Ramathibodi Hospital, the patient was treated with 25 mg/week of etanercept [an anti-tumor necrosis factor (TNF) agent], 25 mg/week of methotrexate, 2 g/day of sulfasalazine, and 5 mg/day of prednisolone. After 6 months of treatment with etanercept, she still had severe polyarthritis. Therefore, the etanercept was discontinued, and tocilizumab, a humanized anti-interleukin (IL)-6 receptor antibody, was started at that time. However, we could not use a standard dose of tocilizumab for SJIA (8 mg/kg every 2 weeks) in the early treatment period because of the patient’s socioeconomic situation. Therefore, she received tocilizumab at a dose of 8 mg/kg every 4 weeks. She partially responded to the tocilizumab; her IL-6 level slightly declined from 1105.0 to 574.2 pg/mL 5 months after starting the treatment. Her disease course still waxed and waned. Her arthritis relapsed while receiving the tocilizumab. Therefore, pulse methylprednisolone at 1 g/month, leflunomide at 20 mg/dose, and hydroxychloroquine at 200 mg/day were gradually added to the tocilizumab regimen. The rheumatologist noticed her first episode of albuminuria when her urine albumin dipstick result was 2+. This proteinuria showed evidence of progression at her 1-year follow-up, when her urinary protein-to-creatinine ratio (UPCR) exhibited deterioration from 0.87 to 3.00 (normal ratio, <0.2). A nephrologist was then consulted to diagnose the cause of the progressive proteinuria on the background of refractory SJIA.
On physical examination, her vital signs were normal. She was cachectic (body weight, <3rd percentile) and had a short stature (height, <10th percentile). Her wrists, knees, and ankles were stiff and inflamed. There were no signs or symptoms of edema. Other physical findings were unremarkable. Her urinalysis showed an inactive sediment. Significant proteinuria was confirmed by a 24-h urine collection method, which showed a total urine protein of 1295 mg/day (1792 mg/1.73m2/day). Blood chemistry analysis showed hypoalbuminemia (2.68 g/dL), a normal serum cholesterol level (152 mg/dL), and a normal serum creatinine level (0.47 mg/dL). Infectious screenings were negative for hepatitis B, hepatitis C, and human immunodeficiency viral infection. Other diagnostic investigation results are listed in Table 1.Table 1
Clinical characteristics and laboratory results
|Parameters||Before amyloidosis treatment||At 1-year follow-up|
|- Number of joints involved||19||11|
|- CHAQ-DI score||1.37||1.25|
|- IL-6, pg/mL||624.5 (0–7)||528.7 (0–7)|
|- ESR, mm/h||72 (5–20)||10 (5–20)|
|- CRP, mg/L||76.23 (<5)||3.40 (<5)|
Data are presented as the laboratory result with reference range in parentheses unless otherwise indicated
CHAQ-DI Childhood Health Assessment Questionnaire Disability Index, IL-6 interleukin-6, ESR erythrocyte sedimentation rate, CRP C-reactive protein
Renal biopsy findings
The renal tissue contained eight nonsclerotic glomeruli. The glomeruli were unremarkable. The mesangium showed focal expansion without hypercellularity. Depositions of acellular eosinophilic amorphous material were seen in the glomerular hilum, mesangium, arteriolar wall, and interstitium (Fig. 1a, b). The material demonstrated fuchsinophilic staining, and Congo red staining was positive (Fig. 1c, d) with apple green birefringence under polarized microscopy. Mild tubular atrophy and interstitial fibrosis were also seen. An immunofluorescence study was negative for IgG, IgM, IgA, C3, C1q, fibrinogen, kappa, and lambda. Electron microscopy revealed randomly oriented fibrils of 8 to 10 nm in diameter in the mesangium, interstitium, and arteries (Fig. 2a, b). The glomerular basement membrane was unremarkable, but the podocytes showed partial foot process effacement under electron microscopy. These biopsy findings confirmed renal amyloidosis.Fig. 1
Depositions of amorphous eosinophilic material (arrow) in the (a) glomerular hilum and (b) arteriolar wall (×400, periodic acid–Schiff). Positive Congo red staining in the (c) mesangium and (d) arteriolar wall and interstitium (×400, Congo red)Fig. 2
Electron micrograph shows (a) fibrillary deposits in the arteriolar wall and interstitium (×12,000). b Randomly oriented fibrils measuring 8 to 10 nm in diameter (×40,000)
Clinical follow-up after renal biopsy
Because the amyloidosis was secondary to uncontrolled SJIA, the tocilizumab was increased from a dose of 8 mg/kg every 4 weeks to a dose of 8 mg/kg every 2 weeks. We also started enalapril at 5 mg/day (0.12 mg/kg/day) for an additional antiproteinuric effect. The other drugs were continued at their same dosages. Two months later, the patient’s Childhood Health Assessment Questionnaire Disability Index score decreased. Her UPCR had also decreased from 3.00 to 0.92, and her arthritis improved 3 months after the tocilizumab increment. At the 1-year follow-up, her UPCR had decreased to 0.23 and renal function remained stable, with a serum creatinine concentration of around 0.42 to 0.52 mg/dL. Her C-reactive protein concentration had returned to normal and her IL-6 concentration had slightly decreased. Other follow-up investigation results are listed in Table 1.
MEFV mutation analysis
A 3-mL venous blood sample was collected from the patient for DNA extraction. Next-generation sequencing was performed by SureSelect V5 using the Illumina HiSeq 4000 platform. Sanger sequencing was performed for variant verification. Variants of the MEFV gene (NM#000243, transcript ID: ENST00000219596) were analyzed. A heterozygous c.442G > C (pE148Q) mutation in the MEFV gene was identified.
Renal amyloidosis is a rare cause of proteinuria in children. The prevalence of amyloidosis is higher in patients with JIA than in the general pediatric population [, ], and among the seven subtypes of JIA, SJIA is associated with the highest prevalence of amyloidosis [, ]. In the present case, amyloidosis occurred 10 years after the onset of SJIA, similar to a previous study . In many types of amyloidosis, the kidneys are the predominant organ involved. Proteinuria is the most common clinical presentation .
The MEFV gene encodes a protein called pyrin or marenostrin, which inhibits the processing of IL-1β to an active form through the regulation of nuclear factor-KB and caspase-1 . Pyrin deficiency results in uncontrolled production of active IL-1β . The MEFV gene is also responsible for familial Mediterranean fever, which is an autosomal recessive disorder . Multiple mutations (polymorphisms) of the MEFV gene in one allele have been reported in patients with SJIA [–, ]. The present patient only had a heterozygous E148Q mutation in the MEFV gene, which is a common polymorphism. Whether the E148Q polymorphism is a benign or disease-causing mutation remains controversial. Although glutamic acid has been conserved at position 148 throughout evolution, thus favoring mutation, the general populations of many ethnicities exhibit a high frequency of E148Q (Egyptian, 6.66%; Jewish, 4.30%–6.60%; Greek, 1.30%; Japanese, 23.70% [, –]; and Thai, 24.3% [unpublished data]). Without other polymorphisms in the MEFV gene, the presentation of amyloidosis of our patient may or may not have been related to the heterozygous E148Q mutation. Further functional studies with large samples from both the general population and patients with SJIA are needed to clarify the penetrance of E148Q.
Although we cannot classify the specific subtype of the amyloidogenic precursor in our country, AA amyloidosis is the most common subtype in patients with various chronic inflammatory diseases, including SJIA [–]. Therefore, we treated the patient in this case based on current evidence regarding treatment of AA amyloidosis. The main principle of management is suppression of the inflammatory process and control of the underlying disease [, ]. The clinical characteristics and treatment of JIA-related renal amyloidosis are shown in Table 2. Three of six patients were diagnosed with SJIA, and two responded to chlorambucil or leflunomide treatment for renal amyloidosis [, ]. Cantarini et al.  could not demonstrate the efficacy of colchicine in one patient with SJIA because of loss to follow-up. Some studies have shown the efficacy of chlorambucil for JIA-related amyloidosis [, ]. One case-cohort study  revealed that 80% of patients receiving chlorambucil achieved 10-year survival compared with only 24% of patients who had never received cytostatic treatment. However, there is lack of supporting evidence from randomized controlled trials (RCTs) regarding the efficacy of chlorambucil and leflunomide in patients with JIA-related amyloidosis.Table 2
Clinical characteristics and treatment of reported patients with secondary amyloidosis related to juvenile idiopathic arthritis
aFever, hepatosplenomegaly, lymphadenopathy, and serositis
F female, JIA juvenile idiopathic arthritis, ESR erythrocyte sedimentation rate, CRP C-reactive protein, eGFR estimated glomerular filtration rate, FU follow-up, NA not available, UPCR urine protein-to-creatinine ratio, MTX methotrexate, CSA cyclosporine A, GCs glucocorticoids, ETA etanercept, CRB chlorambucil, GI gastrointestinal, ATM sodium aurothiomalate, BCL bucillamine, D-PEN D-penicillamine, SFZ sulfasalazine, TCZ tocilizumab, DMARDs disease-modifying anti-rheumatic drugs, ADA adalimumab, COL colchicine, CYC cyclophosphamide, INF infliximab, ANA anakinra, ABA abatacept, HCQ hydroxychloroquine, LFN leflunomide
Many studies have also demonstrated inadequate efficiency of anti-TNF-α medications for treatment of SJIA; remission was achieved in less than half of all patients in these studies, and relapsing disease was common [–]. Two studies have shown the efficacy of anti-TNF therapy in treating amyloidosis secondary to autoimmune diseases, including JIA [, ]. A retrospective study of 15 patients with amyloidosis with underlying rheumatic diseases revealed that 54.5% of patients receiving infliximab (81%) or etanercept (19%) showed renal improvement and 17% showed renal progression at the end of follow-up . Two RCTs demonstrated the efficacy of tocilizumab for the treatment of refractory SJIA in patients without amyloidosis [, ]. Several retrospective studies have demonstrated clinical improvement rates of around 70% in adult patients with rheumatic disease with amyloidosis after tocilizumab treatment [, ]. However, patients with SJIA were not included in these studies; thus, the efficacy of tocilizumab treatment for amyloidosis secondary to SJIA remains unclear.
The present patient developed secondary amyloidosis despite receiving tocilizumab, which can be explained by her uncontrolled SJIA. The patient still had persistent active arthritis while receiving a tocilizumab dose of 8 mg/kg every 4 weeks. Although she had no systemic features, her inflammatory markers (IL-6 level of 624.5 pg/mL and C-reactive protein level of 76.2 mg/L) were persistently high, reflecting insufficient control of her disease activity. After the tocilizumab was increased from every 4 weeks to every 2 weeks, which is the same dosage reported in previous RCTs [, ], her clinical symptoms of arthritis were relieved and her inflammatory markers decreased within 3 months. She had stable renal function, and her UPCR had decreased to 0.23 at the 1-year follow-up. Therefore, tocilizumab is beneficial in treating amyloidosis secondary to SJIA when conventional therapies fail. However, the minimum dose of tocilizumab in such patients is 8 mg/kg every 2 weeks.
We have described a case of renal amyloidosis secondary to refractory SJIA in a carrier of the E148Q mutation in the MEFV gene. Physicians should be aware of the possibility of amyloidosis development in patients with SJIA, especially when such patients show progressive proteinuria and uncontrolled disease. Early detection and appropriate treatment will affect clinical outcomes and lead to a better prognosis. Tocilizumab may be beneficial in patients with amyloidosis related to uncontrolled SJIA.
The authors thank the patient and her parent. The authors also thank Dr. Duangrurdee Wattanasirichaigoon and Saisuda Nujarean from the Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand for assisting with the genetic analysis.
The genetic analysis was funded by the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. The patient’s medical expenses were supported by a grant-in-aid from the Universal Health Care Coverage Project of the National Health Security Office (NHSO), Thailand.
Availability of data and materials
Variants of the MEFV gene were analyzed and the data of genetic sequencing were cited from NCBI Sequence Read Archive (SRA). The transcript ID was ENST00000219596 and the reference sequence was NM_000243 and NP_000234. The hyperlink for the repository is http://asia.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000103313;r=16:3242028-3256627.
SC collected the patient’s clinical data and was the main contributor to the writing of the manuscript. SV participated in the data collection and reviewed the manuscript. TTA participated in the preparation and discussion of the genetic data. SW participated in preparation of the pathological data. All authors approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
The patient and her parent received all information regarding this case report. Informed consent for publication was obtained in written form of BMC nephrology from the patient.
Ethics approval and consent to participate
This case report was approved by the ethic committee of the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. Protocol number: ID 09–58-37. The patient gave the informed consent for participation in written form of Ramathibodi hospital.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- T PetterssonYT KonttinenAmyloidosis-recent developmentsSemin Arthritis Rheum201039535636810.1016/j.semarthrit.2008.09.00119022480
- JD SipeMD BensonJN BuxbaumS IkedaG MerliniMJ SaraivaAmyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the international society of AmyloidosisAmyloid2010173–410110410.3109/13506129.2010.52681221039326
- F BergesioAM CicianiM SantostefanoR BrugnanoM ManganaroG PalladiniRenal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosisNephrol Dial Transplant20072261608161810.1093/ndt/gfm04117395661
- N JossK McLaughlinK SimpsonJM Boulton-JonesPresentation, survival and prognostic markers in AA amyloidosisQJM200093853554210.1093/qjmed/93.8.53510924536
- JD GillmorePN HawkinsPathophysiology and treatment of systemic amyloidosisNat Rev Nephrol201391057458610.1038/nrneph.2013.17123979488
- HJ LachmannHJ GoodmanJA GilbertsonJR GallimoreCA SabinJD GillmoreNatural history and outcome in systemic AA amyloidosisN Engl J Med2007356232361237110.1056/NEJMoa07026517554117
- NA AyazS OzenY BilginerM ErguvenE TaskiranE YilmazMEFV mutations in systemic onset juvenile idiopathic arthritisRheumatology (Oxford)2009481232510.1093/rheumatology/ken40918984609
- L CantariniOM LucheriniG SimoniniM GaleazziCT BaldariR CimazSystemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV geneRheumatol Int201232246546710.1007/s00296-009-1331-720044784
- HM LotfyME KandilMS IssacS SalahNA IsmailMA Abdel MawlaMEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritisMol Diagn Ther201418554955710.1007/s40291-014-0105-424862656
- J DavidO VouyioukaBM AnsellA HallP WooAmyloidosis in juvenile chronic arthritis: a morbidity and mortality studyClin Exp Rheumatol199311185908453805
- JC PackhamMA HallLong-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcomeRheumatology (Oxford)200241121428143510.1093/rheumatology/41.12.142812468825
- K ImmonenA SavolainenH KautiainenM HakalaLongterm outcome of amyloidosis associated with juvenile idiopathic arthritisJ Rheumatol200835590791218381779
- F OnenFamilial Mediterranean feverRheumatol Int200626648949610.1007/s00296-005-0074-316283319
- K MigitaT NakamuraY MaedaT MiyashitaT KogaM TanakaMEFV mutations in Japanese rheumatoid arthritis patientsClin Exp Rheumatol20082661091109419210876
- AY HershkoE Ben-ChetritThe MEFV E148Q allele: a deleterious mutation or harmless variation?Clin Exp Rheumatol2006245 Suppl 42S51S5217067427
- D Marek-YagelI Bar-JosephE PrasY BerkunIs E148Q a benign polymorphism or a disease-causing mutation?J Rheumatol20093610237210.3899/jrheum.09025019820229
- LM DemberEmerging treatment approaches for the systemic amyloidosesKidney Int20056831377139010.1111/j.1523-1755.2005.00535.x16105087
- C DuarteC GomesAJ CorreiaM SalgadoRenal amyloidosis: an uncommon complication of juvenile idiopathic arthritisClin Rheumatol200625454854910.1007/s10067-005-0048-616261284
- A SahaY ChopraJD TheisJA VranaS SethiAA amyloidosis associated with systemic-onset juvenile idiopathic arthritisAm J Kidney Dis201362483483810.1053/j.ajkd.2013.02.37723664546
- AD BilliauF CornillieC WoutersInfliximab for systemic onset juvenile idiopathic arthritis: experience in 3 childrenJ Rheumatol20022951111111412022340
- Y KimuraP PinhoG WalcoG HigginsD HummellI SzerEtanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritisJ Rheumatol200532593594215868633
- RA RussoMM KatsicasClinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agentsJ Rheumatol20093651078108210.3899/jrheum.09095219435972
- RA RussoMM KatsicasM ZelazkoEtanercept in systemic juvenile idiopathic arthritisClin Exp Rheumatol200220572372612412209
- A Fernandez-NebroA OliveMC CastroAH VarelaE RieraMV IrigoyenLong-term TNF-alpha blockade in patients with amyloid a amyloidosis complicating rheumatic diseasesAm J Med2010123545446110.1016/j.amjmed.2009.11.01020399323
- JE GottenbergF Merle-VincentF BentaberryY AllanoreF BerenbaumB FautrelAnti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacyArthritis Rheum20034872019202410.1002/art.1116312847696
- F De BenedettiHI BrunnerN RupertoA KenwrightS WrightI CalvoRandomized trial of tocilizumab in systemic juvenile idiopathic arthritisN Engl J Med2012367252385239510.1056/NEJMoa111280223252525
- S YokotaT ImagawaM MoriT MiyamaeY AiharaS TakeiEfficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trialLancet20083719617998100610.1016/S0140-6736(08)60454-718358927
- A CourtiesG GrateauP PhilippeRM FlipoL AstudilloB Aubry-RozierAA amyloidosis treated with tocilizumab: case series and updated literature reviewAmyloid2015222849210.3109/13506129.2014.100203125585627
- Y OkudaM OhnishiK MatobaK JouyamaA YamadaN SawadaComparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseasesMod Rheumatol201424113714310.3109/14397595.2013.85404824261770
- Y OkudaK TakasugiSuccessful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritisArthritis Rheum20065492997300010.1002/art.2211816947531
- B NowakS JekaP WilandJ SzechinskiRapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumabJoint Bone Spine200976221721910.1016/j.jbspin.2008.08.00719196533
- M HakalaK ImmonenM KorpelaM VasalaMJ KauppiGood medium-term efficacy of tocilizumab in DMARD and anti-TNF-alpha therapy resistant reactive amyloidosisAnn Rheum Dis201372346446510.1136/annrheumdis-2012-20215623148310